Median Technologies to attend the 2017 ASCO Annual Meeting, June 2-6, 2017, McCormick Place, Chicago, IL, USA

Sophia Antipolis, France

Press Release – For immediate release – May 31, 2017 – 17:45 CEST –

Median Technologies, the Imaging Phenomics Company™, announced today that it will be exhibiting at the 2017 ASCO Annual Meeting, June 2-6 at the McCormick Place, Chicago, IL, USA (exhibition dates: June 3-6).

Median Technologies will share and showcase its offering for imaging solutions and services in clinical trials, featuring both its iBiopsy® [1] platform and its Lesion Management Solution (LMS) imaging platform, at booth #7113.

For the first time at an oncology conference, Median will present its iBiopsy® platform. iBiopsy®, or Imaging Biomarker Phenotyping System, is a groundbreaking imaging platform that combines non-invasive image biomarkers with phenomics. This unique combination of science and technology is at the very core of precision medicine because it can provide insights into development of novel therapies and individualized treatment strategies. Remarkably, iBiopsy® can measure disease and treatment response without an invasive and costly biopsy.

The ASCO Annual Meeting is the world’s premier oncology conference, organized by the American Society of Clinical Oncology, the largest oncology society in the world. Each year, the ASCO conference brings together more than 35,000 oncologists from all around the globe, and is attended by all medical, educational and industrial stakeholders involved in the field of oncology worldwide. More about the ASCO Annual Meeting:

[1] iBiopsy® is an Investigation Device; Limited to United States law to investigational use.

Download 20170531_PR_ASCO2017_final_EN-1.pdf